|
|
Line 1: |
Line 1: |
| {{DISPLAYTITLE:Cinnarizine}}
| | [[Redirect:Cinnarizine]] |
| | |
| '''Cinnarizine''' is an [[antihistamine]] and [[:Category:Calcium channel blockers|calcium channel]] blocker of the diphenylmethylpiperazine group.<ref name="DrugBank">{{Cite web|url=https://go.drugbank.com/drugs/DB00568 |title=Cinnarizine|website= DrugBank Online|access-date=2022-04-13}}</ref>
| |
| | |
| ==Potential uses==
| |
| Cinnarizine is typically used for [[vertigo]]/[[Ménière's disease]], vestibular conditions, [[tinnitus]], [[nystagmus]], motion sickness, [[nausea]] and [[vomiting]].<ref name="DrugBank" /> Cinnarizine relaxes the blood vessels; when used together with a nootropic, such as [[piracetam]], it improves [[cerebral blood flow|blood flow to the brain]].<ref name="DrugBank" />
| |
| | |
| ==Pharmacodynamics==
| |
| Cinnarizine has also known to have antiserotoninergic and antidopaminergic effects.<ref name="DrugBank" /><ref name="Kariya">{{cite journal | vauthors = Kariya S, Isozaki S, Masubuchi Y, Suzuki T, Narimatsu S | title = Possible pharmacokinetic and pharmacodynamic factors affecting parkinsonism inducement by cinnarizine and flunarizine | journal = Biochemical Pharmacology | volume = 50 | issue = 10 | pages = 1645–50 | date = November 1995 | pmid = 7503767 | doi = 10.1016/0006-2952(95)02057-8 }}</ref> Cinnarizine blocks muscarinic acetylcholine receptors, meaning it acts against vomiting.<ref name="DrugBank" />
| |
| | |
| The half-maximal inhibitory concentration of cinnarizine for smooth muscle contraction inhibition is 60mM.<ref>{{cite journal | vauthors = Silver PJ, Dachiw J, Ambrose JM, Pinto PB | title = Effects of the calcium antagonists perhexiline and cinnarizine on vascular and cardiac contractile protein function | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 234 | issue = 3 | pages = 629–35 | date = September 1985 | pmid = 3162016 }}</ref><ref>{{cite journal | vauthors = López MG, Moro MA, Castillo CF, Artalejo CR, García AG | title = Variable, voltage-dependent, blocking effects of nitrendipine, verapamil, diltiazem, cinnarizine and cadmium on adrenomedullary secretion | journal = British Journal of Pharmacology | volume = 96 | issue = 3 | pages = 725–31 | date = March 1989 | pmid = 2720300 | pmc = 1854390 | doi = 10.1111/j.1476-5381.1989.tb11874.x }}</ref>
| |
| {| class="wikitable"
| |
| |-
| |
| ! Action of cinnarizine !! Target of action
| |
| |-
| |
| | Calcium ion channel antagonist || [[T-type calcium channel]]s
| |
| |-
| |
| | Antihistaminic || [[H1 receptor]]s
| |
| |-
| |
| | Antiserotinergic || [[5-HT2 receptor|5-HT<sub>2</sub> receptor]]s<ref>{{cite journal | vauthors = Pukhal'skaya TG, Kolosova OA, Men'shikov MY, Vein AM | title = Effects of calcium antagonists on serotonin-dependent aggregation and serotonin transport in platelets of patients with migraine | journal = Bulletin of Experimental Biology and Medicine | volume = 130 | issue = 7 | pages = 633–5 | date = July 2000 | pmid = 11140571 | doi = 10.1007/BF02682090 }}</ref>
| |
| |-
| |
| | Antidopaminergic || [[D2 receptor]]s
| |
| |}
| |
| | |
| ==Costs and availability==
| |
| It is not available in the [[United States]] or [[Canada]].{{Citation needed|date=2022}}
| |
| | |
| ==See also ==
| |
| *[[Allergy]]
| |
| *[[Histamine]]
| |
| *[[Vertigo]]
| |
| *[[Ménière's disease]]
| |
| *[[Channelopathy]]
| |
| | |
| ==Learn more ==
| |
| *[https://go.drugbank.com/drugs/DB00568 Cinnarizine] - DrugBank Online
| |
| | |
| == References ==
| |
| {{reflist}}
| |
| [[Category:Potential treatments]]
| |
| [[Category:Calcium channel blockers]]
| |
| [[Category:Antihistamines]]
| |
| [[Category:H1 antihistamines]]
| |
| [[Category:Antiemetics]]
| |